Masimo (NSDQ:MASI) met Wall Street’s forecast for its full-year and 4th-quarter earnings, giving its shares a 2% bump yesterday and sending them another 3% higher today.
The Irvine, Calif.-based patient monitoring systems maker reported profits of $$13.8 million, or 23 cents per share, on sales of $112.3 million for the 3 months ended Dec. 31, 2011, for a top-line increase of 6.4% but a bottom-line decline of 14.2%, compared with Q4 2010.
For the full year, Masimo posted profits of $63.7 million, or $1.05 per share, on sales of $406.5 million, up 14% and down 13.4%, respectively, compared with 2010.
Sign up to get our free newsletters delivered straight to your inbox
Analysts on The Street were spot-on with their earnings-per-share forecasts, predicting Q4 profits of 23 cents and full-year EPS of $1.05.
“Masimo finished 2011 with a 12% rise in 4th-quarter product revenue, including 17% growth in our direct business. Strong double-digit sales growth in our U.S. acute care channel and international business, as well as a 16% increase in rainbow revenue, drove our product revenue performance in the quarter,” chairman & CEO Joe Kiani said in prepared remarks. “We also grew our worldwide installed base by 15%, expanding our global reach and demonstrating the continuing demand for our superior Masimo SET pulse oximetry and rainbow SET Pulse CO-Oximetry technology.”
Masimo said it expects to generate revenues of about $483 million this year, with EPS of $1.20 per share – a penny above analysts’ consensus estimate.
MASI shares closed today at $22.22, up 2.9% on the day.
Henry Schein shines, The Street shrugs
Henry Schein (NSDQ:HSIC) posted double-digit sales and earnings increases but left Wall Street unimpressed, with shares closing down a barely perceptible 0.03% today.
The Melville, N.Y.-based medical products giant posted profits of $104.7 million, or $1.15 per share, on sales of $2.34 billion during the three months ended Dec. 31, 2011.
That compares with profits of $93.0 million, or $1 per share, on sales of $2.02 billion during 2010.
For the full year, Schein logged profits of $367.7 million, or $3.97 per share, on sales of $$8.53 billion, up 12.9% and 13.3%, respectively.
HSIC shares closed at $73.13 today, down a hair on the day. Read more
Cynosure swings to Q4 black
Cynosure (NSDQ:CYNO) put some black ink in the ledger for the 4th quarter and slashed its net losses nearly in half.
The Westford, Mass.-based cosmetic device maker posted profits of $1.1 million, or 8 cents per share, on sales of $34.1 million during the three months ended Dec. 31, 2011.
That compares with losses of $798,000, or 6 cents per share, on sales of $22.3 million during the same period in 2010.
For the full year, Cynosure reported losses of $2.9 million, or 23 cents per share, on sales of $110.6 million. The company put up losses of $5.5 million, or 44 cents per share, on sales of $81.8 million in 2010. Read more
Solta Medical returns to black ink
Not to be outdone by Cynosure, fellow cosmetic device maker Solta Medical (NSDQ:SLTM) also returned to 4th-quarter profitability and pared its full-year losses.
The Hayward, Calif.-based company posted profits of $1.0 million, or 2 cents per share, on sales of $33.2 million during the three months ended Dec. 31, 2011.
That compares with losses of $190,000, or 0 EPS, on sales of $30.1 million during the same period in 2010.
For the full year, Solta logged losses of $1.3 million, or 2 cents per share, on sales of $116.0 million. That compares with losses of $2.0 million, or 3 cents per share, on sales of $10.9 million during 2010. Read more
Cutera cuts its Q4 losses
Cutera (NSDQ:CUTR), riding a wave from its just-closed acquisition of Iridex, boosted its 4th-quarter sales by 21.9% and pared losses by nearly 31%.
The Brisbane, Calif.-based cosmetic device maker posted losses of $887,000, or 6 cents per share, on sales of $18.5 million during the three months ended Dec. 31, 2011.
That compares with losses of $1.3 million, or 9 cents per share, on sales of $15.2 million during the same period last year. Read more
Sales slide for NeuroMetrix, but losses are nearly cut in half during Q4, 2011
Fourth-quarter and full-year sales for NeuroMetrix (NSDQ:NURO) were each off by nearly 25%, but the medical device maker still managed to pare its losses during both periods and announced the closure of an $8.5 million public offering.
The Waltham, Mass.-based company posted losses of $2.4 million, or 63 cents per share, on sales of $2.4 million during the three months ended Dec. 31, 2011.
That compares with losses of $4.2 million, or $1.09 per share, on sales of $3.1 million during the same period in 2010.
For the full year, NeuroMetrix reported losses of 10.0 million, or $2.59 per share, on sales of $10.4 million. That compares with losses of $16.9 million, or $4.40 per share, on sales of $13.9 million during 2010. Read more
Electromed’s Q2 profits plunge 92%
Second-quarter profits plummeted for Electromed (NSDQ:ELMD) despite a 2.2% top-line gain due to “underperformance by a number of former Clinical Area Managers,” according to a press release.
The New Prague, Minn.-based airway clearance company posted profits of $25,000, or 0 EPS, on sales of $4.8 million during the three months ended Dec, 31, 2011.
That compares with profits of $292,000, or 4 cents per share, on sales of $4.7 million during the same period in 2010. Read more
IsoRay’s Q2 sales slide, losses widen
IsoRay (NYSE:ISR) posted lower sales and larger losses for its fiscal 2nd quarter.
The Richland, Wash.-based brachytherapy maker posted losses of $631,000, or 2 cents per share, on sales of $1.23 million during the three months ended Dec. 31, 2011.
That compares with losses of $231,000, or 1 cent per share, on sales of $1.24 million during the same period last year. Read more
Q2 sales rise, losses fall for Precision Optics
Precision Optics (PINK:PEYE) raised its fiscal 2nd-quarter top line by 13.3% and shaved losses by 1.8%.
The Gardner, Mass.-based micro-optic device maker posted losses of $325,000, or 27 cents per share, on sales of $494,000 during the three months ended Dec. 31, 2011.
That compares with losses of $331,000, or 33 cents per share, on sales of $436,000 million during the same period in 2010. Read more
Q2 sales, profits rise for Fonar
Fonar (NSDQ:FONR) raised its fiscal 2nd-quarter sales and profits by 16.3% and 12.7%, respectively.
The Melville, N.Y.-based MRI device maker posted profits of $1.5 million, or 24 cents per share, on sales of $9.3 million during the three months ended Dec. 31, 2011.
That compares with profits of $1.4 million, also 24 cents per share, on sales of $8.0 million during the same period in 2010. Read more
Given Imaging’s Q4, 2011 sales & profits jump
Given Imaging (NSDQ:GIVN) raised sales and profits during the 4th quarter and full year.
The Yoqneam, Israel-based PillCam maker posted profits of $5.6 million, or 18 cents per share, on sales of $48.5 million during the three months ended Dec. 31, 2011.
That compares with profits of $3.2 million, or 11 cents per share, on sales of $44.9 million during the same period in 2010.
For the full year, profits were $12.0 million, or 39 cents per share, on sales of $178.0 million. That compares with profits of $8.5 million, or 28 cents per share, on sales of $157.8 million during 2010. Read more
Conmed swings to Q4 black
Conmed (NSDQ:CNMD) swung to black ink during the 4th quarter.
The Utica, N.Y.-based surgical device maker posted profits of $7.0 million, or 24 cents per share, on sales of $184.1 million during the three months ended Dec. 31, 2011.
That compares with losses of $25.1 million, or 90 cents per share, on sales of $185.6 million during the same period in 2010.
For the full year, Conmed logged profits of $30.3 million, or $1.05 per share, on sales of $713.7 million. That compares with profits of $752,000, or 3 cents per share, on sales of $725.1 million during 2010. Read more
Urologix boosts sales, but losses more than double
Urologix (NSDQ:ULGX) boosted its 2nd-quarter sales, but its losses more than doubled.
The Minneapolis-based prostate ablation device maker posted losses of $1.1 million, or 8 cents per share, on sales of $4.7 million during the three months ended Dec. 31, 2011.
That compares with losses of $712,000, or 5 cents per share, on sales of $3.3 million during the same period last year. Read more